The Zocere Story
Zocere, Inc. is a New Mexico-based biotech company that is developing novel therapeutics for neurological diseases, including stroke, and offering services to other entities developing stroke-related diagnostics and treatments. We have licensed patented technology for a derivative of the brain-specific STEP protein, tyrosine phosphatase, developed at the University of New Mexico. This technology is the foundation for a novel, generation next therapeutic treatment of stroke that shows promise of becoming the first injectable neuroprotectant drug in the market.
Wayne Laslie President and CEOWayne Laslie has more than 30 years of experience in pharmaceutical commercialization in U.S. and international markets.
Kenton H. Zavitz, PhD Chief Scientific OfficerKenton H. Zavitz, PhD, has more than 15 years of biotechnology and pharmaceutical experience, ranging from drug discovery and clinical development to pre-commercialization.
Meet Zocere’s Board of Directors
“We’ve coupled a strong leadership team and board to accelerate the development and commercialization pathways of our stroke therapeutics with a tight financial strategy to leverage investment capital.” Wayne Laslie, CEO Zocere, Inc.
Proud supporter of the American Stroke Association